Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Nuvalent, Inc. have bought $0 and sold $119.73M worth of Nuvalent, Inc. stock.
On average, over the past 5 years, insiders at Nuvalent, Inc. have bought $52.71M and sold $48.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 650,000 shares for transaction amount of $21.77M was made by Flynn James E (director) on 2022‑11‑03.
2024-06-24 | Sale | Shair Matthew | director | 2,000 0.0031% | $80.22 | $160,438 | -0.30% | |
2024-06-14 | Sale | Conley Emily | director | 5,000 0.0076% | $77.56 | $387,776 | +1.34% | |
2024-06-06 | Sale | Miller Deborah Ann | Chief Legal Officer | 1,810 0.0026% | $75.41 | $136,484 | -3.06% | |
2024-06-06 | Sale | Miller Deborah Ann | Chief Legal Officer | 8,000 0.0122% | $80.40 | $643,213 | -3.06% | |
2024-05-28 | Sale | Shair Matthew | director | 2,000 0.0031% | $67.22 | $134,438 | +16.88% | |
2024-05-15 | Sale | Conley Emily | director | 5,000 0.0075% | $69.09 | $345,450 | +2.54% | |
2024-05-13 | Sale | Shair Matthew | director | 37,500 0.0579% | $65.84 | $2.47M | +10.06% | |
2024-05-06 | Sale | Shair Matthew | director | 37,500 0.0587% | $69.48 | $2.61M | +2.56% | |
2024-05-02 | Sale | Miller Deborah Ann | Chief Legal Officer | 3,000 0.0047% | $72.07 | $216,203 | -2.55% | |
2024-04-29 | Sale | Shair Matthew | director | 39,500 0.0613% | $67.51 | $2.67M | +3.99% | |
2024-04-22 | Sale | Shair Matthew | director | 37,500 0.0578% | $63.65 | $2.39M | +8.48% | |
2024-04-15 | Sale | Shair Matthew | director | 37,500 0.0588% | $65.56 | $2.46M | +5.83% | |
2024-04-15 | Sale | Conley Emily | director | 5,000 0.0078% | $65.52 | $327,607 | +5.83% | |
2024-04-08 | Sale | Shair Matthew | director | 37,500 0.0585% | $68.44 | $2.57M | +0.70% | |
2024-04-04 | Sale | Miller Deborah Ann | Chief Legal Officer | 3,000 0.0048% | $73.60 | $220,787 | -4.14% | |
2024-04-01 | Sale | Shair Matthew | director | 37,500 0.0584% | $76.92 | $2.88M | -10.27% | |
2024-03-28 | Sale | Miller Deborah Ann | Chief Legal Officer | 22,000 0.0344% | $75.20 | $1.65M | -7.51% | |
2024-03-27 | Sale | Hack Andrew A. F. | director | 880,000 1.3042% | $72.77 | $64.04M | -8.93% | |
2024-03-25 | Sale | Shair Matthew | director | 39,500 0.0619% | $76.77 | $3.03M | -8.59% | |
2024-03-22 | Sale | Noci Darlene | Chief Development Officer | 20,000 0.0312% | $77.51 | $1.55M | -9.94% |
Hack Andrew A. F. | director | 2697267 5.7117% | $78.78 | 2 | 1 | +4.5% |
Shair Matthew | director | 232522 2.7538% | $78.78 | 0 | 32 | |
Turner Christopher Durant | Chief Medical Officer | 14513 0.0232% | $78.78 | 0 | 6 | |
Conley Emily | director | 2507 0% | $78.78 | 0 | 4 | |
Noci Darlene | Chief Development Officer | 33300 0% | $78.78 | 0 | 31 | |
Protopapas Anna | director | 0 0% | $78.78 | 0 | 1 | |
Balcom Alexandra | Chief Financial Officer | 0 0% | $78.78 | 0 | 2 | |
Miller Deborah Ann | Chief Legal Officer | 33300 0% | $78.78 | 0 | 24 | |
Flynn James E | director | 650000 1.0378% | $78.78 | 3 | 0 | +13.74% |
Deerfield Management | $1.5B | 30.97 | 19.99M | 0% | +$0 | 29.02 | |
Fidelity Investments | $660.41M | 13.62 | 8.79M | +0.8% | +$5.24M | 0.04 | |
Paradigm BioCapital Advisors LP | $313.71M | 6.47 | 4.18M | +8.29% | +$24.02M | 11.38 | |
The Vanguard Group | $256.21M | 5.29 | 3.41M | +2.16% | +$5.42M | 0.01 | |
Perceptive Advisors | $209.01M | 4.31 | 2.78M | -4.61% | -$10.1M | 0.14 | |
BlackRock | $203.38M | 4.2 | 2.71M | -0.47% | -$956,421.33 | 0.01 | |
Bain Capital Life Sciences Investors Llc | $202.54M | 4.18 | 2.7M | -24.6% | -$66.08M | 20.35 | |
Fairmount Funds Management LLC | $144.52M | 2.98 | 1.92M | 0% | +$0 | 15.75 | |
State Street | $113.69M | 2.35 | 1.51M | -11% | -$14.05M | 0.01 | |
Commodore Capital, LP | $111.72M | 2.31 | 1.49M | +11.77% | +$11.77M | 7.87 | |
Darwin Global Management Ltd | $107.9M | 2.23 | 1.44M | +2,390.49% | +$103.57M | 16.04 | |
Boxer Capital, LLC | $84.12M | 1.74 | 1.12M | 0% | +$0 | 4.21 | |
T. Rowe Price | $64.44M | 1.33 | 858,161 | -22.43% | -$18.64M | 0.01 | |
Geode Capital Management | $51.19M | 1.06 | 681,596 | +4.1% | +$2.02M | 0.01 | |
Driehaus Capital Management LLC | $50.53M | 1.04 | 672,877 | -28.24% | -$19.89M | 0.51 | |
Wellington Management Company | $44.57M | 0.92 | 593,602 | -41.42% | -$31.52M | 0.01 | |
Alger | $40.88M | 0.84 | 544,372 | +69.08% | +$16.7M | 0.2 | |
Lord Abbett | $33.95M | 0.7 | 452,192 | -0.43% | -$147,100.89 | 0.12 | |
D. E. Shaw & Co. | $33.44M | 0.69 | 445,382 | -4.87% | -$1.71M | 0.05 | |
Candriam S C A | $21.33M | 0.44 | 284,009 | +1.43% | +$300,360.00 | 0.14 | |
Deep Track Capital Lp | $20.61M | 0.43 | 274,512 | -39% | -$13.18M | 0.1 | |
Northern Trust | $20.06M | 0.41 | 267,165 | -4.78% | -$1.01M | <0.01 | |
Helm Capital Management LLC | $19.66M | 0.41 | 261,874 | New | +$19.66M | 0.58 | |
Charles Schwab | $18.18M | 0.38 | 242,044 | +2.18% | +$387,689.67 | <0.01 | |
Voya Investment Management LLC | $17.13M | 0.35 | 228,115 | +163.09% | +$10.62M | 0.02 | |
Invesco | $14.65M | 0.3 | 195,142 | +14.39% | +$1.84M | <0.01 | |
Franklin Templeton Investments | $14.57M | 0.3 | 194,037 | +10.6% | +$1.4M | <0.01 | |
Bank of Montreal | $14.6M | 0.3 | 194,178 | +117.99% | +$7.9M | <0.01 | |
Dimensional Fund Advisors | $14.48M | 0.3 | 192,813 | -32.06% | -$6.83M | <0.01 | |
Morgan Stanley | $13.87M | 0.29 | 184,671 | -32.38% | -$6.64M | <0.01 | |
HERITAGE ASSET MANAGEMENT INC | $14.16M | 0.28 | 183,645 | New | +$14.16M | 0.07 | |
Goldman Sachs | $13.39M | 0.28 | 178,369 | -18.41% | -$3.02M | <0.01 | |
Victory Capital Management Inc | $13.23M | 0.27 | 176,245 | -4.79% | -$666,498.84 | 0.01 | |
Silverarc Capital Management Llc | $11.85M | 0.24 | 157,750 | -18.26% | -$2.65M | 3.49 | |
Affinity Asset Advisors | $11.26M | 0.23 | 150,000 | -14.29% | -$1.88M | 2 | |
Arrowmark Colorado Holdings Llc | $10.58M | 0.22 | 140,959 | -29.18% | -$4.36M | 0.03 | |
Soleus Capital Management, L.P. | $9.71M | 0.2 | 129,288 | -59.96% | -$14.54M | 0.09 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $9.41M | 0.19 | 125,302 | New | +$9.41M | 0.24 | |
Nicholas Investment Partners, L.P. | $9.22M | 0.19 | 122,790 | +55.04% | +$3.27M | 1.04 | |
BNY Mellon | $8.4M | 0.17 | 111,917 | -6.28% | -$562,949.76 | <0.01 | |
Citadel Advisors LLC | $8.25M | 0.17 | 109,884 | -47.46% | -$7.45M | 0.01 | |
Rafferty Asset Management Llc | $8.16M | 0.17 | 108,668 | -14.47% | -$1.38M | 0.02 | |
Citigroup | $7.69M | 0.16 | 102,431 | +48.76% | +$2.52M | 0.01 | |
Ikarian Capital LLC | $7.63M | 0.16 | 101,601 | -60.64% | -$11.75M | 2.18 | |
Ubs Asset Management Americas Inc | $7.37M | 0.15 | 98,123 | +295.29% | +$5.5M | <0.01 | |
Bank of America | $6.78M | 0.14 | 90,261 | -0.37% | -$25,155.15 | <0.01 | |
RHENMAN & PARTNERS ASSET MANAGEMENT AB | $6.57M | 0.14 | 87,500 | -22.52% | -$1.91M | 0.63 | |
UBS | $6.31M | 0.13 | 84,018 | +4.2% | +$254,329.85 | <0.01 | |
Woodline Partners LP | $4.92M | 0.1 | 65,492 | 0% | +$0 | 0.05 | |
Nuveen | $4.82M | 0.1 | 64,208 | +0.2% | +$9,536.43 | <0.01 |